Mast cell-derived prostaglandin D2 inhibits colitis and colitis-associated colon cancer in mice

Cancer Research

Volumn 74, Issue 11, 2014, Pages 3011-3019

  Iwanaga, Koichi ^a   Nakamura, Tatsuro ^a   Maeda, Shingo ^a   Aritake, Kosuke ^b   Hori, Masatoshi ^a   Urade, Yoshihiro ^b   Ozaki, Hiroshi ^a   Murata, Takahisa ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN; IMMUNOGLOBULIN RECEPTOR; ISOMERASE; LIPOCALIN; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN R2 D-ISOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLITIS; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; HISTOPATHOLOGY; INTRACELLULAR SIGNALING; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COLONIC NEOPLASMS; DEFICIENCY; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; COLITIS; COLONIC NEOPLASMS; GENOTYPE; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTAGLANDIN D2; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902183864     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2792     Document Type: Article

References (39)

1. Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal cancer in inflammatory bowel disease: A population-based study from Olmsted county, Minnesota. Gastroenterology 2006;130:1039-46.
2. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009;15: 199-207.
3. Popivanova BK, Kitamura K, WuY, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008;118:560-70.
4. Doherty GA, Byrne SM, Molloy ES, Malhotra V, Austin SC, Kay EW, et al. Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer 2009;9:207.
5. Kim YJ, Hong KS, Chung JW, Kim JH, Hahm KB. Prevention of colitisassociated carcinogenesis with infliximab. Cancer Prev Res 2010;3: 1314-33.
6. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:376-89.
7. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340: 1888-99.
8. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
9. Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa H, Kakudo S, et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 2001;298: 411-9.
10. Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000;287:2013-7.
11. Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A 2007;104: 20979-84.
12. Yamamoto Y, Otani S, Hirai H, Nagata K, Aritake K, Urade Y, et al. Dual functions of prostaglandin D2 in murine contact hypersensitivity viaDP and CRTH2. Am J Pathol 2011;179:302-14.
13. Murata T, Aritake K, Matsumoto S, Kamauchi S, Nakagawa T, Hori M, et al. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A 2011;108: 19802-7.
14. Murata T, Aritake K, Tsubosaka Y, Maruyama T, Nakagawa T, Hori M, et al. Anti-inflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement. Proc Natl Acad Sci U S A 2013;110:5205-10.
15. Mohri I, Taniike M, Taniguchi H, Kanekiyo T, Aritake K, Inui T, et al. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J Neurosci 2006;26: 4383-93.
16. Suzuki F, Hayashi H, Hayaishi O. Transport of prostaglandin D2 into brain. Brain Res 1986;385:321-8.
17. Gavert N, Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. J Cell Biochem 2007;102:820-8.
18. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the betacatenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005;280:26565-72.
19. Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol 2004;11:1068-75.
20. Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 2012;33:723-31.
21. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005;167:835-48.
22. May E, Lambert C, Holtmeier W, Hennemann A, Zeitz M, Duchmann R. Regional variation of the alphabeta T cell repertoire in the colon of healthy individuals and patients with Crohn's disease. Hum Immunol 2002;63:467-80.
23. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001;292:1115-8.
24. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23->IL-17 axis. J Immunol 2007;178:8138-47.
25. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003;24:985-90.
26. Hirota Y, Suzuki M, Katsube N. Thromboxane A2 up-regulates neutrophil elastase release in Syrian hamsters with trinitrobenzene sulfonic acid-induced colitis. J Pharmacol Sci 2005;98:430-8.
27. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002;62:63-6.
28. Imada A, Shijubo N, Kojima H, Abe S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 2000;15:1087-93.
29. Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 2010;16: 2257-65.
30. Fleischmann A, Schlomm T, Kollermann J, Sekulic N, Huland H, Mirlacher M, et al. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009;69:976-81.
31. Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004;17:690-5.
32. Wedemeyer J, Galli SJ. Decreased susceptibility of mast celldeficient Kit(W)/Kit(W-v) mice to the development of 1, 2-dimethylhydrazine- induced intestinal tumors. Lab Invest 2005;85: 388-96.
33. Muto S, Katsuki M, Horie S. Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice. Cancer Sci 2007;98:1549-56.
34. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135-42.
35. Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 2008;29:880-6.
36. Minocha A, Thomas C, Omar R. Lack of crucial role of mast cells in pathogenesis of experimental colitis in mice. Dig Dis Sci 1995;40: 1757-62.
37. Cuzzocrea S, Ianaro A, Wayman NS, Mazzon E, Pisano B, Dugo L, et al. The cyclopentenone prostaglandin 15-deoxy-delta(12, 14)- PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 2003;138: 678-88.
38. Hammad H, Kool M, Soullie T, Narumiya S, Trottein F, Hoogsteden HC, et al. Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med 2007;204:357-67.
39. Nakamura M, Yamaguchi S, Motoyoshi K, Negishi M, Saito-Taki T, Matsumoto K, et al. Anti-tumor effects of prostaglandin D2 and its metabolits, 15-deoxy-D12, 14-PGJ2, by peroxisome proliferator-activated receptor (PPAR)g-dependent and -independent pathways. Inflamm Regen 2011:31:189-95.